Dokumente im Korb
Helmholtz Zentrum München
|
Imprint
PuSH - Publication Server of Helmholtz Zentrum München
Navigation
Home
Deutsch
Research
Advanced Search
Browse by ...
... Journal
... Publication Type
... Research Data
... Publication Year
Publication overview
Support & Contact
Contact persons
Help
Data protection
Raia, V.* ; Schilling, M.* ; Böhm, M.* ; Hahn, B.* ;
Kowarsch, A.
; Raue, A.* ; Sticht, C.* ; Bohl, S.* ; Saile, M.* ; Möller, P.* ; Gretz, N.* ; Timmer, J.* ;
Theis, F.J.
; Lehmann, W.D.* ; Lichtner, P.* ; Klingmüller, U.*
Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-Cell lymphoma allows prediction of therapeutic targets.
Cancer Res.
71
, 693-704 (2011)
DOI
PMC
Open Access Green
as soon as Postprint is submitted to ZB.
Abstract
Metrics
Extra information
Primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) share a frequent constitutive activation of JAK (Janus kinase)/STAT signaling pathway. Because of complex, nonlinear relations within the pathway, key dynamic properties remained to be identified to predict possible strategies for intervention. We report the development of dynamic pathway models based on quantitative data collected on signaling components of JAK/STAT pathway in two lymphoma-derived cell lines, MedB-1 and L1236, representative of PMBL and cHL, respectively. We show that the amounts of STAT5 and STAT6 are higher whereas those of SHP1 are lower in the two lymphoma cell lines than in normal B cells. Distinctively, L1236 cells harbor more JAK2 and less SHP1 molecules per cell than MedB-1 or control cells. In both lymphoma cell lines, we observe interleukin-13 (IL13)-induced activation of IL4 receptor α, JAK2, and STAT5, but not of STAT6. Genome-wide, 11 early and 16 sustained genes are upregulated by IL13 in both lymphoma cell lines. Specifically, the known STAT-inducible negative regulators CISH and SOCS3 are upregulated within 2 hours in MedB-1 but not in L1236 cells. On the basis of this detailed quantitative information, we established two mathematical models, MedB-1 and L1236 model, able to describe the respective experimental data. Most of the model parameters are identifiable and therefore the models are predictive. Sensitivity analysis of the model identifies six possible therapeutic targets able to reduce gene expression levels in L1236 cells and three in MedB-1. We experimentally confirm reduction in target gene expression in response to inhibition of STAT5 phosphorylation, thereby validating one of the predicted targets. Cancer Res; 71(3); 693-704. ©2010 AACR.
Altmetric
Additional Metrics?
[➜Log in]
Tags
Icb_LungSys
Annotations
Special Publikation
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Corresponding Author
Keywords
IL 13; JAK; lymphoma; modeling; STAT
Keywords plus
ISSN (print) / ISBN
0008-5472
e-ISSN
1538-7445
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Journal
Cancer Research
Quellenangaben
Volume: 71,
Issue: 3,
Pages: 693-704
Article Number: ,
Supplement: ,
Series
Publisher
American Association for Cancer Research (AACR)
Publishing Place
Philadelphia, Pa.
University
University place
Faculty
Publication date
0000-00-00
Application number
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Bioinformatics and Systems Biology (IBIS)
Grants
Copyright